Sugi Predict

Sugi Predict / Compounds / SCHEMBL128039

SCHEMBL128039

SCHEMBL128039

Nc1nc(-c2ccc(F)c(C(F)(F)F)c2)cs1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MPL P40238 6/20 1.00
▸ RAB9A P51151 8/20 0.56
▸ ALDH1A1 P00352 6/20 0.56
▸ ALOX5 P09917 1/20 0.56
▸ SMN1; SMN2 Q16637 6/20 0.55
▸ NPC1 O15118 5/20 0.55
▸ MEN1 O00255 4/20 0.55
▸ KMT2A Q03164 4/20 0.55
▸ MAPT P10636 7/20 0.54
▸ KDM4E B2RXH2 3/20 0.54
▸ LTA4H P09960 4/20 0.52
▸ NFKB1 P19838 2/20 0.51
▸ NFKB2 Q00653 2/20 0.51
▸ RELA Q04206 2/20 0.51
▸ AR P10275 1/20 0.51
▸ GFER P55789 1/20 0.51
▸ HPGD P15428 2/20 0.48
▸ TP53 P04637 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL474197 0.88 MPL (0.78) MPLRAB9AALDH1A1ALOX5SMN1; SMN2
SCHEMBL474200 0.83 MPL (0.71) MPLRAB9AALDH1A1ALOX5SMN1; SMN2
SCHEMBL21301005 0.83 MPL (0.71) MPLRAB9AALDH1A1ALOX5SMN1; SMN2
SCHEMBL18724008 0.83 MPL (0.71) MPLRAB9AALDH1A1ALOX5SMN1; SMN2
SCHEMBL17400589 0.83 MPL (0.71) MPLRAB9AALDH1A1ALOX5SMN1; SMN2
SCHEMBL126685 0.82 MPL (0.69) MPLRAB9AALDH1A1ALOX5SMN1; SMN2
SCHEMBL1800105 0.81 MPL (0.68) MPLRAB9AALDH1A1ALOX5SMN1; SMN2
SCHEMBL19626513 0.81 MPL (0.68) MPLRAB9AALDH1A1SMN1; SMN2NPC1
SCHEMBL25243665 0.80 MPL (0.67) MPLRAB9AALDH1A1ALOX5SMN1; SMN2
SCHEMBL31084655 0.80 MPL (0.67) MPLRAB9AALDH1A1ALOX5SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49111-E1 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2022-06-21 — — US disclosed
EP-2963036-B1 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF ASTELLAS PHARMA INC (JP) 2019-08-28 — — EP disclosed
EP-3153511-B1 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF BLADDER/URINARY TRACT DISEASES ASTELLAS PHARMA INC (JP) 2019-05-15 — — EP disclosed
US-9951060-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2018-04-24 — — US disclosed
US-9951060-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2018-04-24 — — US disclosed
US-20170197955-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-07-13 — — US disclosed
US-20170197955-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-07-13 — — US disclosed
EP-3153511-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2017-04-12 — — EP disclosed
US-9562044-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2017-02-07 — — US disclosed
US-9562044-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2017-02-07 — — US disclosed
WO-2010004390-A1 QUINAZOLINE DIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-01-14 — — WO disclosed
US-20090325987-A1 QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2009-12-31 — — US disclosed
US-20090325987-A1 QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2009-12-31 — — US disclosed
US-20090325987-A1 QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2009-12-31 — — US disclosed
US-20080076771-A1 Thrombopoietin Receptor Agonists REITER LAWRENCE A 2008-03-27 — — US disclosed
EP-1874765-A2 UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF Proskelia SAS (FR) 2008-01-09 — — EP disclosed
EP-1794156-A2 TROMBOPOIETIN RECEPTOR AGONISTS Pfizer Products Incorporated (US) 2007-06-13 — — EP disclosed
WO-2007036769-A1 AMINOTHIAZOLE DERIVATIVES AS AGONISTS OF THE THROMBOPOIETIN RECEPTOR PFIZER PRODUCTS INC. (US) 2007-04-05 — — WO disclosed
WO-2006117211-A2 UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF PROSKELIA SAS (FR) 2006-11-09 — — WO disclosed
WO-2006033005-A2 THROMBOPOIETIN RECEPTOR AGONISTS PFIZER PRODUCTS INC. (US) 2006-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197955-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF CHRM3, CHRM2, TRPM2 MPL 3647/4885RAB9A 2439/4885ALDH1A1 1551/4885
US-20090325987-A1 QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS TRPA1, TRPV1, TRPC3 MPL 4421/4885RAB9A 2497/4885ALDH1A1 871/4885
US-20080076771-A1 Thrombopoietin Receptor Agonists MPL, THPO, TBXA2R MPL 1/4885RAB9A 2219/4885ALDH1A1 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.